Compare Ecopetrol SA (EC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Regeneron Pharmaceuticals Inc — how do they compare? Ecopetrol SA trades at $15.83 (market cap $30.44B), while Regeneron Pharmaceuticals Inc trades at $678.4 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.3× Ecopetrol SA's market cap, and Ecopetrol SA pays the higher dividend (4.06%). Which is the better fit depends on your goals.
| EC | REGN | |
|---|---|---|
Market Cap | $30.44B | $69.66B |
Sector | Energy | Health |
52-Week High | $16.58 | $812.27 |
52-Week Low | $8.29 | $542.52 |
Enterprise Value | $58.23B | $63.61B |
Dividend Yield | 4.06% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.16, up 1.76% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company maintains solid profitability with an 8.76% net margin and 13.01% ROE, though revenue has declined from $159.6T in 2022 to $119.7T in 2025. Recent developments include a finalized labor agreement with the USO union and S&P affirming its BB- credit rating with a stable outlook on June 17, 2026.
The stock presents a mixed outlook: valuation appears reasonable with a P/E of 11.39, but earnings misses and declining revenue pose risks. Analyst consensus is cautious with a $14.63 price target below current levels. Key opportunities include stable cash flow and dividend payments, while risks involve oil price volatility and execution challenges in a competitive energy sector.
Regeneron (REGN) trades at $656.11, down 1.05% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and has beaten EPS estimates for three consecutive quarters. Recent positive news includes FDA and EMA acceptance of cemdisiran for gMG treatment and selection for an FDA manufacturing review pilot program, reinforcing growth prospects.
Outlook remains positive with a consensus price target of $764.50, implying 16.5% upside. Key opportunities include earnings momentum and regulatory advancements, while risks involve competitive pressures and dependence on key drug performance. Institutional sentiment is strongly bullish with 69% buy ratings, though legal investigations and market volatility warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
